
At the pulse of heart disease
We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.
Download the Cardior Factsheet
News
Hanover, Germany, December 1, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced that Orly Vardeny, PharmD, MS, joins its Board of Directors as a permanent guest.
Hanover, Germany, November 3, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO).

On September 14, 2022, we have officially opened our new headquarters in Hollerithallee 20, 30419 Hanover. Our scientific roots have always been in the Hanover region and we look forward to continuing our international growth from our new headquarters, demonstrating the scientific excellence and entrepreneurial spirit we have experienced in this city.